Global Allergic Conjunctivitis Market (2020 to 2027) -
12 Apr 2021
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering. Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.According to this research, AllergicAllergic Conjunctivitis Market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.Many Pharmaceutical companies are trying to develop many new possibilities of treatment for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials.The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Allergic Conjunctivitis Market and Patients Analysis5.1 Market5.2 Patient Numbers5.3 Treated Patient Numbers6. Share Analysis - Global Allergic Conjunctivitis6.1 Country Market Share6.2 Patients Population Share6.3 Treated Patients Population Share6.4 By Disease Type Share7. India - Allergic Conjunctivitis Analysis7.1 Patient Numbers7.2 Treated Patient Numbers7.3 Market8. China - Allergic Conjunctivitis Analysis8.1 Patient Numbers8.2 Treated Patient Numbers8.3 Market9. Japan - Allergic Conjunctivitis Analysis9.1 Patient Numbers9.2 Treated Patient Numbers9.3 Market10. United States - Allergic Conjunctivitis Analysis10.1 Patient Numbers10.2 Treated Patient Numbers10.3 Market11. United Kingdom - Allergic Conjunctivitis Analysis11.1 Patient Number11.2 Treated Patient Numbers11.3 Market12. France - Allergic Conjunctivitis Analysis12.1 Patient Numbers12.2 Treated Patient Numbers12.3 Market13. Germany - Allergic Conjunctivitis Analysis13.1 Patient Numbers13.2 Treated Patient Numbers13.3 Market14. Italy - Allergic Conjunctivitis Analysis14.1 Patient Numbers14.2 Treated Patient Numbers14.3 Market15. Spain - Allergic Conjunctivitis Analysis15.1 Patient Numbers15.2 Treated Patient Numbers15.3 Market16. Disease Type - Global Allergic Conjunctivitis Market16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)16.2 Vernal Keratoconjunctivitis (VKC)16.3 Atopic Keratoconjunctivitis (AKC)16.4 Giant Papillary Conjunctivitis (GPC)17. Global Allergic Conjunctivitis Pipeline Drugs17.1 Zerviate17.2 OTX-DP (Dexamethasone Insert)17.3 ADX-10217.4 PRT276117.5 CVXL-007417.6 AK-00217.7 Bertilimumab17.8 Reproxalap17.9 ST-26617.10 SYL-11601118. Company Analysis18.1 Santen Pharmaceutical18.1.1 Company Overview18.1.2 Recent Developments18.1.3 Financial Insight18.2 Alcon Inc. (Novartis)18.2.1 Company Overview18.2.2 Recent Developments18.2.3 Financial Insight18.3 Portola Pharmaceuticals Inc.18.3.1 Company Overview18.3.2 Recent Developments18.3.3 Financial Insight18.4 Ocular Therapeutix Inc.18.4.1 Company Overview18.4.2 Recent Developments18.4.3 Financial InsightFor more information about this report visit
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.